The Ability of Songha Night ® to Improve Sleep in Patients With Mild to Moderate Sleep Disturbances
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Psychophysiologic insomnia
- Severity: mild to moderate
- Duration: subacute to chronic
- Subjects age > 18 and < 65, men or women
- Subject had to give written informed consent
Exclusion Criteria:
- Regular use of psycho-active drugs
- Work in shifts
- Use of psychoactive drugs during the past 30 days
- Any treatment that might interfere with his/her participation in this study and the evaluation of the efficacy or safety of the test drug (e.g. renal insufficiency, hepatic or metabolic dysfunction, cardiovascular disease, psychiatric disorder, myasthenia gravis, delirious state, etc.)
- known hypersensitivity to any of the ingredients of the study drug
- Pregnancy, lactation, women of childbearing potential not using an established contraceptive
- Drug and alcohol abuse
- Participation in another trial within the past 30 days
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
|
|
Experimental: Songha Night ®
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in sleep quality on a 100 mm visual analogue scale (VAS)
Time Frame: baseline, after 2 and 4 weeks of treatment, 1 week after end of treatment
|
baseline, after 2 and 4 weeks of treatment, 1 week after end of treatment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Feeling refreshed score (six point rating scale)
Time Frame: up to week 5
|
up to week 5
|
|
Ability to concentrate and perform well score (six point rating scale)
Time Frame: up to week 5
|
up to week 5
|
|
Night-time total sleeping time
Time Frame: up to week 5
|
up to week 5
|
|
Difficulty in falling asleep (five point rating scale)
Time Frame: up to week 5
|
up to week 5
|
|
Number of awakenings during the night
Time Frame: up to week 5
|
up to week 5
|
|
Physical and mental health state by short form (SF-36) questionnaire
Time Frame: up to week 5
|
up to week 5
|
|
Anxiety by State-Trait Anxiety Inventory
Time Frame: up to week 5
|
up to week 5
|
|
Frequency of adverse events
Time Frame: up to week 5
|
up to week 5
|
|
Global clinical impression on insomnia by short questionnaire
Time Frame: up to week 5
|
up to week 5
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 582.1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.